<DOC>
	<DOCNO>NCT01890577</DOCNO>
	<brief_summary>An observational study describe treatment anaemia patient chronic kidney disease , receive dialysis treatment select study centre South Africa .</brief_summary>
	<brief_title>Study South African Dialysis Patients</brief_title>
	<detailed_description>This multicentre , prospective , observational study describe treatment clinical outcome dialysis patient South Africa . No formal hypothesis test descriptive study . Eligible subject receive either peritoneal haemodialysis , receive Aranesp therapy 3 6 month prior enrolment study , need receive Aranesp time enrolment follow 12 month commencement Aranesp . Data collect include ESA therapy , iron usage , relevant concomitant therapy , haemoglobin concentration , relevant clinical laboratory parameter red cell transfusion .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Adult patient undergo chronic haemodialysis peritoneal dialysis Commenced Aranesp therapy 36 month prior enrolment Erythropoiesis stimulating agent ( ESA ) naive treat another ESA prior commence Aranesp Informed consent obtain Received Aranesp interventional study within 6 month prior start observation period Receive investigational product observation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Erythropoiesis stimulating agent</keyword>
	<keyword>South Africa</keyword>
</DOC>